Yiwen Zhang1, Mingyang Song2,3,4, Lorelei A Mucci1, Edward L Giovannucci1,4. 1. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 2. Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 3. Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts. 4. Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Abstract
PURPOSE: Multivitamin supplement is commonly used among older adults in the United States. Evidence on multivitamin use and prostate cancer risk is limited, and some suggested potential risk for clinically important subtypes of cancer. MATERIALS AND METHODS: A total of 48,137 men from the Health Professionals Follow-up Study were followed from 1986 to 2017. Multivitamin use and frequency were self-reported at baseline and updated biennially. Clinical features of prostate cancer included advanced, lethal and high-grade outcomes. Cox proportional hazards models were used to estimate multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) of multivitamin use and incidence of prostate cancer. RESULTS: The median followup for men without prostate cancer diagnosis or death was 30.7 years. We documented 7,108 incident prostate cancer cases including 564 advanced and 1,065 lethal. Overall, we observed a null association between multivitamin use and risk of prostate cancer. Compared to never-users, men who used multivitamin 10 or more tablets per week had similar risk of advanced (HR: 1.14, 95% CI: 0.77-1.70, Ptrend=0.46) or lethal (HR: 1.07, 95% CI: 0.80-1.44, Ptrend=0.59) prostate cancer, and multivitamin use of 15 years or more was not associated with risk of advanced (HR: 1.10, 95% CI: 0.80-1.50, Ptrend=0.46) or lethal (HR: 1.04, 95% CI: 0.83-1.31, Ptrend=0.13) prostate cancer. CONCLUSIONS: Regular or long-duration multivitamin use among older, generally well-nourished men was not associated with either increased or lower risk of overall or aggressive prostate cancer.
PURPOSE: Multivitamin supplement is commonly used among older adults in the United States. Evidence on multivitamin use and prostate cancer risk is limited, and some suggested potential risk for clinically important subtypes of cancer. MATERIALS AND METHODS: A total of 48,137 men from the Health Professionals Follow-up Study were followed from 1986 to 2017. Multivitamin use and frequency were self-reported at baseline and updated biennially. Clinical features of prostate cancer included advanced, lethal and high-grade outcomes. Cox proportional hazards models were used to estimate multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) of multivitamin use and incidence of prostate cancer. RESULTS: The median followup for men without prostate cancer diagnosis or death was 30.7 years. We documented 7,108 incident prostate cancer cases including 564 advanced and 1,065 lethal. Overall, we observed a null association between multivitamin use and risk of prostate cancer. Compared to never-users, men who used multivitamin 10 or more tablets per week had similar risk of advanced (HR: 1.14, 95% CI: 0.77-1.70, Ptrend=0.46) or lethal (HR: 1.07, 95% CI: 0.80-1.44, Ptrend=0.59) prostate cancer, and multivitamin use of 15 years or more was not associated with risk of advanced (HR: 1.10, 95% CI: 0.80-1.50, Ptrend=0.46) or lethal (HR: 1.04, 95% CI: 0.83-1.31, Ptrend=0.13) prostate cancer. CONCLUSIONS: Regular or long-duration multivitamin use among older, generally well-nourished men was not associated with either increased or lower risk of overall or aggressive prostate cancer.
Authors: Hyun Ja Kim; Edward Giovannucci; Bernard Rosner; Walter C Willett; Eunyoung Cho Journal: J Acad Nutr Diet Date: 2013-10-09 Impact factor: 4.910
Authors: Victoria L Stevens; Marjorie L McCullough; W Ryan Diver; Carmen Rodriguez; Eric J Jacobs; Michael J Thun; Eugenia E Calle Journal: Cancer Causes Control Date: 2005-08 Impact factor: 2.506
Authors: Song-Yi Park; Suzanne P Murphy; Lynne R Wilkens; Brian E Henderson; Laurence N Kolonel Journal: Am J Epidemiol Date: 2011-02-22 Impact factor: 4.897
Authors: Eric A Klein; Ian M Thompson; Catherine M Tangen; John J Crowley; M Scott Lucia; Phyllis J Goodman; Lori M Minasian; Leslie G Ford; Howard L Parnes; J Michael Gaziano; Daniel D Karp; Michael M Lieber; Philip J Walther; Laurence Klotz; J Kellogg Parsons; Joseph L Chin; Amy K Darke; Scott M Lippman; Gary E Goodman; Frank L Meyskens; Laurence H Baker Journal: JAMA Date: 2011-10-12 Impact factor: 56.272
Authors: Michael F Leitzmann; Meir J Stampfer; Kana Wu; Graham A Colditz; Walter C Willett; Edward L Giovannucci Journal: J Natl Cancer Inst Date: 2003-07-02 Impact factor: 13.506